IAM
TEVA icon

Ion Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Ion Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$111M Sell
5,510,000
-32,837,875
-86% -$577M 12.22% 1
2025
Q2 		$643M Sell
38,347,875
-685,625
-2% -$11.1M 35.34% 1
2025
Q1 		$600M Buy
39,033,500
+2,383,500
+7% +$42.6M 38.81% 1
2024
Q4 		$808M Buy
36,650,000
+409,778
+1% +$7.46M 47.03% 1
2024
Q3 		$653M Sell
36,240,222
-89,398
-0.2% -$1.56M 35.18% 1
2024
Q2 		$590M Sell
36,329,620
-2,248,867
-6% -$34.6M 32.96% 1
2024
Q1 		$544M Sell
38,578,487
-1,748,920
-4% -$22M 34.4% 1
2023
Q4 		$421M Buy
40,327,407
+1,504,891
+4% +$14.1M 27.96% 1
2023
Q3 		$396M Buy
38,822,516
+5,759,512
+17% +$53.6M 40.91% 1
2023
Q2 		$249M Buy
33,063,004
+4,872,280
+17% +$39.5M 29.07% 1
2023
Q1 		$249M Buy
28,190,724
+22,993,331
+442% +$227M 26.16% 1
2022
Q4 		$47.4M Buy
+5,197,393
New +$45.4M 6.41% 4
2021
Q4 		– Sell
-1,635,446
Closed -$15.9M – 46
2021
Q3 		$15.9M Buy
+1,635,446
New +$15.3M 2.18% 13
2020
Q3 		– Sell
-5,176,190
Closed -$63.8M – 34
2020
Q2 		$63.8M Buy
+5,176,190
New +$58.5M 10.69% 3
2019
Q1 		– Sell
-1,542,419
Closed -$23.8M – 13
2018
Q4 		$23.8M Buy
+1,542,419
New +$31.6M 6.28% 7
2018
Q1 		– Sell
-281,900
Closed -$5.34M – 10
2017
Q4 		$5.34M Sell
281,900
-173,450
-38% -$2.61M 1.38% 10
2017
Q3 		$8.01M Buy
+455,350
New +$10.2M 2.44% 11
2016
Q3 		– Sell
-113,245
Closed -$5.69M – 18
2016
Q2 		$5.69M Sell
113,245
-278,766
-71% -$14.8M 2.68% 11
2016
Q1 		$21M Sell
392,011
-137,261
-26% -$8.05M 9.58% 6
2015
Q4 		$34.7M Buy
529,272
+385,619
+268% +$23.8M 15.22% 1
2015
Q3 		$8.11M Sell
143,653
-17,400
-11% -$1.13M 11.31% 1
2015
Q2 		$9.52M Buy
161,053
+5,400
+3% +$333K 11.12% 3
2015
Q1 		$9.7M Sell
155,653
-900
-0.6% -$52.3K 10.65% 3
2014
Q4 		$9M Buy
+156,553
New +$8.72M 9.2% 3

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Ion Asset Management's TEVA Position: Q3 2025 in Review

Ion Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 86% in Q3 2025, selling an estimated $577M and leaving 5,510,000 shares worth $111M. The position accounts for 12.22% of the portfolio, ranked #1.

Ion Asset Management first reported a position in TEVA in Q4 2014 and has held it in 24 quarters since. The position peaked at $808M in Q4 2024. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Ion Asset Management held 5,510,000 shares of Teva Pharmaceuticals worth $111M as of Q3 2025.
  • Ion Asset Management sold 32,837,875 Teva Pharmaceuticals shares in Q3 2025, an estimated $577M.
  • Teva Pharmaceuticals made up 12.22% of Ion Asset Management's portfolio in Q3 2025, its #1 holding.
  • Ion Asset Management first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 24 quarters since.
  • Ion Asset Management's Teva Pharmaceuticals position peaked at $808M in Q4 2024.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Ion Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.